[1]杨 安,刘玉娥,申 景.肝门部胆管癌的介入治疗现状及研究进展[J].介入放射学杂志,2021,30(03):312-316.
 YANG An,LIU Yue,SHEN Jing..Interventional treatment of hilar cholangiocarcinoma: its current status and research progress[J].journal interventional radiology,2021,30(03):312-316.
点击复制

肝门部胆管癌的介入治疗现状及研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
312-316
栏目:
综述
出版日期:
2021-03-29

文章信息/Info

Title:
Interventional treatment of hilar cholangiocarcinoma: its current status and research progress
作者:
杨 安 刘玉娥 申 景
Author(s):
YANG An LIU Yu’e SHEN Jing.
Department of Medical Imaging, Shanxi Medical University, Taiyuan, Shanxi Province 030001, China
关键词:
【关键词】 肝门部胆管癌 经皮穿肝胆管引流术 经皮胆道内支架植入术近距离腔内放射治疗经皮胆管内射频消融术 经导管动脉内治疗
文献标志码:
A
摘要:
【摘要】 肝门部胆管癌是最常见且严重威胁患者生命的胆道系统恶性肿瘤。近年来,随着介入放射学的快速多样化发展,介入治疗已逐渐成为肝门部胆管癌的重要的治疗手段,主要包括胆道引流、胆道支架、125I粒子腔内近距离照射、胆道腔内射频消融以及经肝动脉介入治疗等5种方法。如何安全有效的解除胆汁淤积症状、避免胆道再狭窄的发生是当前研究的热点问题。本文就目前临床上针对肝门部胆管癌常用的上述介入治疗方法及其临床疗效作一综述,并进一步展望多种介入治疗手段联合使用在抑制肿瘤进展、提高患者生存质量等方面的临床应用价值。 

参考文献/References:

[1] Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383: 2168-2179.
[2] Capobianco I, Jens R, Nadalin S. Resection for klatskin tumors: technical complexities and results[J]. Transl Gastroenterol Hepatol, 2018, 3: 69.
[3] Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma -evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15: 95-111.
[4] 陈孝平,项 帅. 精准医学时代肝门部胆管癌的治疗[J]. 中华消化外科杂志, 2018, 17:3-8.
[5] 李相成,江王杰.肝门部胆管癌诊治进展[J]. 腹部外科, 2019,32:7-12.
[6] Neuhaus H. Preoperative biliary drainage in hilar cholangiocar-cinoma: when and how?[J]. Endosc Int Open, 2020, 8: E211-E213.
[7] 李富宇,程南生. 肝门部胆管癌的治疗现状与展望[J]. 中国普外基础与临床杂志, 2018, 25:769-774.
[8] 熊 壮,赵本胜. 肝门部胆管癌伴梗阻性黄疸的介入治疗[J].肝胆外科杂志, 2015, 23:163-164.
[9] 李 斌,张柏和,姜小清. 解读不同指南与共识的热点及分歧,重视肝门部胆管癌的规范化诊疗[J]. 中国普外基础与临床杂志, 2016, 23:1293-1298.
[10] Jean-Marc D, Tringali A, Papanikolaou I, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy(ESGE) Clinical Guideline- Updated October 2017[J]. Endoscopy, 2018, 50: 910- 930.
[11] Ba YJ, Yue P, Leung JW, et al. Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma[J]. Endosc Int Open, 2020, 8: E203-E210.
[12] Komaya K, Ebata T, Yokoyama Y, et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: a propensity score matching analysis of resectable perihilar cholangiocarcinoma[J]. Surgery, 2017, 161: 394-404.
[13] 陈 琳,陈孝平. 肝门部胆管癌个体化治疗的现状与思考[J].国际外科学杂志, 2018, 45:361-363.
[14] Choi JH, Lee SH, Min SY, et al. Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction[J]. Sci Rep, 2019, 9: 13207.
[15] Fei T, Xian YT, Jia L, et al. Comparison of unilateral with bilateral metal stenting for malignant hilar biliary obstruction[J]. Surg Laparosc Endosc Percutan Tech, 2019, 29: 43-48.
[16] Gang C, Xia FF, Li HF, et al. Unilateral versus bilateral stent insertion for malignant hilar biliary obstruction[J]. Abdom Radiol(NY), 2017, 42: 2745-2751.
[17] Xue Y, Li DM, Yang F, et al. Self- expanded metallic stent insertion for hilar cholangiocarcinoma: comparison of unilateral and bilateral stenting[J]. J Laparoendosc Adv Surg Tech A, 2019, 29: 1501-1506.
[18] Fu YF, Zhou WJ, Shi YB, et al. Percutaneous stenting for malignant hilar biliary obstruction: a randomized controlled trial of unilateral versus bilateral stenting[J]. Abdom Radiol(NY), 2019, 44: 2900-2908.
[19] Ashat M, Arora S, Klair JS, et al. Bilateral vs unilateral placement of metal stents for inoperable high- grade hilar biliary strictures: a systemic review and meta- analysis[J]. World J Gastroenterol, 2019, 25: 5210-5219.
[20] Lee TH, Moon JH, Park S. Biliary stenting for hilar malignant biliary obstruction[J]. Dig Endosc, 2020, 32: 275-286.
[21] Jiao DC, Huang K, Zhu M, et al. Placement of a newly designed Y- configured bilateral self- expanding metallic stent for hilar biliary obstruction: a pilot study[J]. Dig Dis Sci, 2017, 62: 253-263.
[22] Inoue T, Ibusuki M, Kitano R, et al. Combined side‐by‐side and stent‐in‐stent method for triple metal stenting in patients with malignant hilar biliary obstruction[J]. Dig Endosc, 2019, 31: 698-705.
[23] Dong JS, Gwon DI, Han K, et al. Percutaneous metallic stent placement for palliative management of malignant biliary hilar obstruction[J]. Korean J Radiol, 2018, 19: 597- 605.
[24] Dhondt E, Vanlangenhove P, Geboes K, et al. No evidence of improved efficacy of covered stents over uncovered stents in percutaneous palliation of malignant hilar biliary obstruction: results of a prospective randomized trial[J]. Eur Radiol, 2020, 30: 175-185.
[25] Dolak W, Schwaighofer H, Hellmich B, et al. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: a nationwide retrospective study of 150 consecutive applications[J]. United European Gastroenterol J, 2017, 5: 104-110.
[26] Yuan T, Zhu Y, Wang X, et al. Efficacy and safety evaluation of paclitaxel-loaded metal stents in patients with malignant biliary obstructions[J]. Eur J Surg Oncol, 2019, 45: 816-819.
[27] Hasimu A, Gu JP, Ji WZ, et al. Comparative study of percutaneous transhepatic biliary stent placement with or without iodine-125 seeds for treating patients with malignant biliary obstruction[J]. J Vasc Interv Radiol, 2017, 28: 583-593.
[28] 徐红豆,周卫忠,刘 圣,等. 经皮胆道支架联合125I粒子条腔内植入治疗恶性梗阻性黄疸的疗效分析[J]. 介入放射学杂志, 2020, 29:83-88.
[29] 李家开,侯小明,张金山. 125I粒子植入组织间近距离放射治疗恶性实体瘤的应用进展[J]. 中国介入影像与治疗学, 2019,16:696-699.
[30] Du E, Lin W, Li CY, et al. Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer[J]. Onco Targets Ther, 2017, 10: 2561-2567.
[31] Kubo M, Satoh T, Ishiyama H, et al. Enhanced activated T-cell subsets in prostate cancer patients receiving iodine-125 low- dose-rate prostate brachytherapy[J]. Oncol Rep, 2017, 39: 417-424.
[32] Zhou WZ, Fu YM, Yang ZQ, et al. Study of percutaneous stent placement with iodine-125 seed strand for malignant biliary obstruction[J]. Cardiovasc Intervent Radiol, 2019, 42: 268-275.
[33] Xu XJ, Li J, Juan W, et al. A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice[J]. Cardiovasc Intervent Radiol, 2018, 41: 206-217.
[34] 胡小四,庞 青,刘会春,等. 经皮胆道支架联合导管载入式125I粒子治疗局部进展期肝外胆管癌的疗效评价与预后因素分析[J]. 介入放射学杂志, 2019, 28:369-375.
[35] 胡章明,李坤峰,姚宜斌,等. 胆道支架联合125I粒子条对恶性梗阻性黄疸的治疗效果[J]. 介入放射学杂志, 2020, 29:59-62.
[36] 潘洪涛,刘会春,费圣贤,等. 胆道支架联合125I粒子腔内照射治疗肝门胆管癌的临床疗效[J]. 中华放射学杂志, 2016, 50:393-396.
[37] 焦德超,周学良,韩新巍,等. 新型一体化可携带125I粒子胆道内外引流管的设计与临床应用[J]. 介入放射学杂志, 2019,28:252-257.
[38] 李宗明,焦德超,韩新巍,等. 125Ⅰ粒子双链放疗引流管在恶性阻塞性黄疸治疗中的初步应用[J]. 郑州大学学报(医学版),2019, 54:646-649.
[39] 王剑宇,徐 浩,许 伟,等. 支架联合内或外125I粒子条治疗恶性梗阻性黄疸临床研究[J]. 介入放射学杂志, 2019, 28:874-877.
[40] Lu J, Guo JH, Zhu HD, et al. Palliative treatment with radiation- emitting metallic stents in unresectable Bismuth type Ⅲ or Ⅳ hilar cholangiocarcinoma[J]. ESMO Open, 2017, 2: e000242.
[41] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 40: 277-292.
[42] Sofi AA, Khan MA, Das A, et al. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a systematic review and meta-analysis[J]. Gastrointest Endosc, 2018, 87: 944-95.
[43] Zheng X, Bo Z Y, Wan W, et al. Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: a systematic review and meta-analysis[J]. J Dig Dis, 2016, 17: 716-724.
[44] Mizandari M, Kumar J, Pai M, et al. Interventional radiofre-quency ablation: a promising therapeutic modality in the mana-gement of malignant biliary and pancreatic duct obstruction[J]. J Cancer, 2018, 9: 629-637.
[45] Kadayifci A, Atar M, Forcione DG, et al. Radiofrequency ablation for the management of occluded biliary metal stents[J]. Endoscopy, 2016, 48: 1096-1101.
[46] Schmidt A, Bloechinger M, Weber A, et al. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma[J]. United European Gastroenterol J, 2016, 4: 570-579.
[47] Cui W, Fan W, Lu M, et al. The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: a single-institution experience[J]. BMC Cancer, 2017, 17: 288.
[48] 梁钰安,梁自安,李奋强,等. 125I放射性粒子支架植入联合TACE治疗肝门部胆管癌的临床疗效对比分析[J]. 介入放射学杂志, 2016, 25:821-825.
[49] 陈耀庭,姚和瑞,孙宏亮,等. 肝动脉灌注化疗联合热疗治疗肝门部胆管癌的临床价值[J]. 中山大学学报(医学科学版),2014, 35:539-544.
[50] Zheng WH,Yu T, Luo YH, et al. Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma[J]. World J Gastrointest Oncol, 2019, 11: 489-498.
[51] White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholan-giocarcinoma: a prospective, observational study[J]. J Vasc Interv Radiol, 2019, 30: 1185-1192.
[52] Zhen Y, Liu B, Chang Z, et al. A pooled analysis of transar-terial radioembolization with yttrium- 90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma[J]. Onco Targets Ther, 2019, 12: 4489-4498.
[53] Jakubowski CD, Azad NS. Immune checkpoint inhibitor therapy in biliary tract cancer(cholangiocarcinoma)[J]. Chin Clin Oncol, 2020, 9: 2.
[54] Sato K, Glaser S, Alvaro D, et al. Cholangiocarcinoma: novel therapeutic targets[J]. Expert Opin Ther Targets, 2020, 24: 345-357.

相似文献/References:

[1]王雪英,闻利红.肝门部胆管癌患者PTBD术后长期置管引流的观察和护理体会[J].介入放射学杂志,2016,(07):640.
 WANG Xue-ying,WEN Li-hong.Observation and nursing care for patients with hilar cholangiocarcinoma receiving long-term indwelling catheter drainage after percutaneous transhepatic biliary drainage [J].journal interventional radiology,2016,(03):640.
[2]梁钰安,梁自安,李奋强,等.125I放射性粒子支架植入联合TACE治疗肝门部胆管癌的临床疗效对比分析[J].介入放射学杂志,2016,(09):821.
 LIANG Yu- an,LIANG Zi- an,LI Fen- qiang,et al.Implantation of radioactive 125I seed stent combined with TACE for the treatment of hilar cholangiocar- cinoma: comparative analysis of curative effect[J].journal interventional radiology,2016,(03):821.

备注/Memo

备注/Memo:
(收稿日期:2020-03-10)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-03-25